Effects of melatonin treatment in septic newborns

Eloisa Gitto, Malgorzata Karbownik, Russel J Reiter, Dun Xian Tan, Salvatore Cuzzocrea, Pietro Chiurazzi, Santa Cordaro, Giuseppina Corona, Giuseppe Trimarchi, Ignazio Barberi

Research output: Contribution to journalArticle

365 Citations (Scopus)

Abstract

Free radicals have been implicated in the pathogenesis of neonatal sepsis and its complications. This study was conducted to determine the changes in the clinical status and the serum levels of lipid peroxidation products [malondialdehyde (MDA) and 4-hydroxylalkenals (4-HDA)] in 10 septic newborns treated with the antioxidant melatonin given within the first 12 h after diagnosis. Ten other septic newborns in a comparable state were used as "septic" controls, while 10 healthy newborns served as normal controls. A total of 20 mg melatonin was administered orally in two doses of 10 mg each, with a 1-h interval. One blood sample was collected before melatonin administration and two additional blood samples (at 1 and 4 h) were collected after melatonin administration to assess serum levels of lipid peroxidation products. Serum MDA + 4-HDA concentrations in newborns with sepsis were significantly higher than those in healthy infants without sepsis; in contrast, in septic newborns treated with melatonin there was a significant reduction (p < 0.05) of MDA + 4-HDA to the levels in the normal controls at both 1 and 4 h (p < 0.05). Melatonin also improved the clinical outcome of the septic newborns as judged by measurement of sepsis-related serum parameters after 24 and 48 h. Three of 10 septic children who were not treated with melatonin died within 72 h after diagnosis of sepsis; none of the 10 septic newborns treated with melatonin died. To our knowledge, this is the first study where melatonin was given to human newborns.

Original languageEnglish (US)
Pages (from-to)756-760
Number of pages5
JournalPediatric Research
Volume50
Issue number6
StatePublished - 2001

Fingerprint

Melatonin
Newborn Infant
Sepsis
Malondialdehyde
Therapeutics
Serum
Lipid Peroxidation
Free Radicals
Antioxidants

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Gitto, E., Karbownik, M., Reiter, R. J., Xian Tan, D., Cuzzocrea, S., Chiurazzi, P., ... Barberi, I. (2001). Effects of melatonin treatment in septic newborns. Pediatric Research, 50(6), 756-760.

Effects of melatonin treatment in septic newborns. / Gitto, Eloisa; Karbownik, Malgorzata; Reiter, Russel J; Xian Tan, Dun; Cuzzocrea, Salvatore; Chiurazzi, Pietro; Cordaro, Santa; Corona, Giuseppina; Trimarchi, Giuseppe; Barberi, Ignazio.

In: Pediatric Research, Vol. 50, No. 6, 2001, p. 756-760.

Research output: Contribution to journalArticle

Gitto, E, Karbownik, M, Reiter, RJ, Xian Tan, D, Cuzzocrea, S, Chiurazzi, P, Cordaro, S, Corona, G, Trimarchi, G & Barberi, I 2001, 'Effects of melatonin treatment in septic newborns', Pediatric Research, vol. 50, no. 6, pp. 756-760.
Gitto E, Karbownik M, Reiter RJ, Xian Tan D, Cuzzocrea S, Chiurazzi P et al. Effects of melatonin treatment in septic newborns. Pediatric Research. 2001;50(6):756-760.
Gitto, Eloisa ; Karbownik, Malgorzata ; Reiter, Russel J ; Xian Tan, Dun ; Cuzzocrea, Salvatore ; Chiurazzi, Pietro ; Cordaro, Santa ; Corona, Giuseppina ; Trimarchi, Giuseppe ; Barberi, Ignazio. / Effects of melatonin treatment in septic newborns. In: Pediatric Research. 2001 ; Vol. 50, No. 6. pp. 756-760.
@article{564ab4ef56154a739cd3444151fae35d,
title = "Effects of melatonin treatment in septic newborns",
abstract = "Free radicals have been implicated in the pathogenesis of neonatal sepsis and its complications. This study was conducted to determine the changes in the clinical status and the serum levels of lipid peroxidation products [malondialdehyde (MDA) and 4-hydroxylalkenals (4-HDA)] in 10 septic newborns treated with the antioxidant melatonin given within the first 12 h after diagnosis. Ten other septic newborns in a comparable state were used as {"}septic{"} controls, while 10 healthy newborns served as normal controls. A total of 20 mg melatonin was administered orally in two doses of 10 mg each, with a 1-h interval. One blood sample was collected before melatonin administration and two additional blood samples (at 1 and 4 h) were collected after melatonin administration to assess serum levels of lipid peroxidation products. Serum MDA + 4-HDA concentrations in newborns with sepsis were significantly higher than those in healthy infants without sepsis; in contrast, in septic newborns treated with melatonin there was a significant reduction (p < 0.05) of MDA + 4-HDA to the levels in the normal controls at both 1 and 4 h (p < 0.05). Melatonin also improved the clinical outcome of the septic newborns as judged by measurement of sepsis-related serum parameters after 24 and 48 h. Three of 10 septic children who were not treated with melatonin died within 72 h after diagnosis of sepsis; none of the 10 septic newborns treated with melatonin died. To our knowledge, this is the first study where melatonin was given to human newborns.",
author = "Eloisa Gitto and Malgorzata Karbownik and Reiter, {Russel J} and {Xian Tan}, Dun and Salvatore Cuzzocrea and Pietro Chiurazzi and Santa Cordaro and Giuseppina Corona and Giuseppe Trimarchi and Ignazio Barberi",
year = "2001",
language = "English (US)",
volume = "50",
pages = "756--760",
journal = "Pediatric Research",
issn = "0031-3998",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Effects of melatonin treatment in septic newborns

AU - Gitto, Eloisa

AU - Karbownik, Malgorzata

AU - Reiter, Russel J

AU - Xian Tan, Dun

AU - Cuzzocrea, Salvatore

AU - Chiurazzi, Pietro

AU - Cordaro, Santa

AU - Corona, Giuseppina

AU - Trimarchi, Giuseppe

AU - Barberi, Ignazio

PY - 2001

Y1 - 2001

N2 - Free radicals have been implicated in the pathogenesis of neonatal sepsis and its complications. This study was conducted to determine the changes in the clinical status and the serum levels of lipid peroxidation products [malondialdehyde (MDA) and 4-hydroxylalkenals (4-HDA)] in 10 septic newborns treated with the antioxidant melatonin given within the first 12 h after diagnosis. Ten other septic newborns in a comparable state were used as "septic" controls, while 10 healthy newborns served as normal controls. A total of 20 mg melatonin was administered orally in two doses of 10 mg each, with a 1-h interval. One blood sample was collected before melatonin administration and two additional blood samples (at 1 and 4 h) were collected after melatonin administration to assess serum levels of lipid peroxidation products. Serum MDA + 4-HDA concentrations in newborns with sepsis were significantly higher than those in healthy infants without sepsis; in contrast, in septic newborns treated with melatonin there was a significant reduction (p < 0.05) of MDA + 4-HDA to the levels in the normal controls at both 1 and 4 h (p < 0.05). Melatonin also improved the clinical outcome of the septic newborns as judged by measurement of sepsis-related serum parameters after 24 and 48 h. Three of 10 septic children who were not treated with melatonin died within 72 h after diagnosis of sepsis; none of the 10 septic newborns treated with melatonin died. To our knowledge, this is the first study where melatonin was given to human newborns.

AB - Free radicals have been implicated in the pathogenesis of neonatal sepsis and its complications. This study was conducted to determine the changes in the clinical status and the serum levels of lipid peroxidation products [malondialdehyde (MDA) and 4-hydroxylalkenals (4-HDA)] in 10 septic newborns treated with the antioxidant melatonin given within the first 12 h after diagnosis. Ten other septic newborns in a comparable state were used as "septic" controls, while 10 healthy newborns served as normal controls. A total of 20 mg melatonin was administered orally in two doses of 10 mg each, with a 1-h interval. One blood sample was collected before melatonin administration and two additional blood samples (at 1 and 4 h) were collected after melatonin administration to assess serum levels of lipid peroxidation products. Serum MDA + 4-HDA concentrations in newborns with sepsis were significantly higher than those in healthy infants without sepsis; in contrast, in septic newborns treated with melatonin there was a significant reduction (p < 0.05) of MDA + 4-HDA to the levels in the normal controls at both 1 and 4 h (p < 0.05). Melatonin also improved the clinical outcome of the septic newborns as judged by measurement of sepsis-related serum parameters after 24 and 48 h. Three of 10 septic children who were not treated with melatonin died within 72 h after diagnosis of sepsis; none of the 10 septic newborns treated with melatonin died. To our knowledge, this is the first study where melatonin was given to human newborns.

UR - http://www.scopus.com/inward/record.url?scp=0035204767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035204767&partnerID=8YFLogxK

M3 - Article

VL - 50

SP - 756

EP - 760

JO - Pediatric Research

JF - Pediatric Research

SN - 0031-3998

IS - 6

ER -